6/9/25 We are currently making changes to reflect the new Health Sciences Division structure. Thank you for your patience while we make the transition.

Sign in
Back
Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes
Journal article   Peer reviewed

Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes

Alicia J. Jenkins, Rachel L. OConnell, Andrzej S. Januszewski, Angela C. Webster, Timothy M. E. Davis, Meg J. Jardine, Russell S. Scott, Marja-Riitta Taskinen, Anthony C. Keech and FIELD Trial Study Grp
Diabetes research and clinical practice, Vol.210, pp.111612-111612
01/04/2024
DOI: https://doi.org/10.1016/j.diabres.2024.111612
Handle:
https://hdl.handle.net/10523/40978

Abstract

Endocrinology & Metabolism Life Sciences & Biomedicine Science & Technology
Globally approximate to 10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of effects in late-stage kidney disease is limited. We report new FIELD substudy data and call for further kidney outcomes data.

Metrics

8 Record Views

Details

Logo image